Skip to main content

Table 4 Adverse events in the study patients (n = 89)

From: Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy

Event

No. of patients (%)

Constipation

12 (13.5)

Local reaction

2 (2.2)

Pruritus

2 (2.2)

Flu-like symptoms

2 (2.2)

Abdominal cramps

1 (1.1)

Transient skin rash

1 (1.1)

Bloating

1 (1.1)

Meteorism

1 (1.1)

Nausea

1 (1.1)

Transient vaginal spotting

1 (1.1)

Urticariaa

1 (1.1)

Vertigo

1 (1.1)

Allergic reactionb

1 (1.1)

Serious adverse events

1 (1.1)

Adverse events leading to treatment discontinuation

1 (1.1)

Total

20 (22.5)

  1. aExacerbation of previous disease
  2. bleading to treatment discontinuation